VELUM INC

Velum, Inc. is a Cambridge, Massachusetts-based biopharmaceutical R&D company specializing in the design and development of protease-stable therapeutic peptides for metabolic diseases. The company's core platform uses novel N-terminal chemical modification strategies to protect endocrine hormone peptides — including GLP-1, GIP, PYY, and GHRH analogues — from rapid enzymatic degradation in the bloodstream, extending their half-life while preserving receptor potency. Velum's lead programs target obesity, type 2 diabetes, and neurological conditions such as traumatic brain injury, and are developed in collaboration with academic partners including Tufts University. The company has received eight SBIR/STTR awards totaling over $5.4 million from NIH and HHS since 2018.